RADNOR, Pa., June 19 /PRNewswire/ -- ADVERTISEMENT - The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:
Schiffrin Barroway Topaz & Kessler, LLP is Co-Lead Counsel for the ERISA plaintiffs in the In re Merck & Co. Inc. Securities, Derivative, & ERISA Litigation, MDL No. 1658, pending in the U.S. District Court for the District of New Jersey. The Court recently ruled that claims for violations of the Employee Retirement Income Security Act of 1974 ("ERISA") relating to the failure of Merck & Co. Inc. ("Merck" or the "Company") (NYSE: MRK) to disclose material facts relating to Vytorin cannot be pursued as part of the ERISA action dealing with issues relating to Vioxx and should be pursued in a separate case. To date, lawsuits have been filed that allege that the investments in the Merck Common Stock Fund within the Merck & Co., Inc. Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, or the Merck Puerto Rico Employee Savings & Security Plan (collectively, the "Merck Plans") have declined substantially because Merck breached its fiduciary duties to participates of the Merck Plans when it failed to disclose material facts regarding Vytorin.
If you wish to discuss this action or have any questions concerning
this notice or your rights or interests with respect to these matters and
are or were a participant in the Merck & Co., Inc. Employee Savings &
Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings
Plan, or the Merck Puerto Rico Employee Savings & Security Plan during the
class period of April 1, 2006 through March 31, 2008, and were invested in
the Merck Common Stock Fund, please contact Schiffrin Barroway Topaz &
Ke
'/>"/>
| SOURCE Schiffrin Barroway Topaz & Kessler, LLP Copyright©2008 PR Newswire. All rights reserved |